Viloxazine for ADHD in Korean children and teens
Part of Mental health clinical trials.
This study tests a new extended-release medication called viloxazine for Korean children and teens with ADHD. The goal is to see if it can help improve attention and reduce hyperactivity compared to a placebo (a pill with no medicine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a Korean child or teen between 6 and 17 years old.
- You have been diagnosed with ADHD by a doctor, and your symptoms are moderately severe or worse.
- You weigh at least 20 kg (44 lbs) if you are 6 to 11, or 35 kg (77 lbs) if you are 12 to 17.
- You are not currently taking an ADHD medication that works well enough, or you are willing to stop it for at least a week before starting the study drug.
- You do not have a history of seizures, brain disorders, or other serious medical conditions that might interfere with the study.
- You (and your parent or guardian) agree to follow the study rules and give permission to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether viloxazine extended-release can reduce ADHD symptoms in children ages 4–5. It also checks safety in preschool-age kids, including heart and nervous-system side effects.
This trial tests a new extended-release medication called Onyda XR (clonidine) in children aged 6 to 12 who have both ADHD and Oppositional Defiant Disorder. The goal is to see if it helps with symptoms like inattention, hyperactivity, and defiant behavior, and if it is safe.
This trial tests whether the medication Dyanavel XR (a long-acting amphetamine) can help reduce fatigue in adults with ADHD. It is for people who have both ADHD and significant tiredness, and who are not currently taking stimulant ADHD drugs.
This study compares stimulant and non-stimulant ADHD medicines in kids who have not taken ADHD medication before. It also studies how these treatments affect brain “reward” processes, which may be linked to substance-use risk.
This trial tests whether omega-3 fatty acids can improve attention and hyperactivity in people with ADHD. It compares omega-3 treatment against a placebo to see if it helps reduce symptoms.
This study tests a new device and algorithm that may help diagnose ADHD in children and teens. It compares results from kids already diagnosed with ADHD to those without, using a wearable monitor and performance tests.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.